El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc-by (c) Martínez-Bosch, Neus et al., 2016
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/150708

The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Current treatments for pancreatic ductal adenocarcinoma (PDA) are ineffective, making this the 4th leading cause of cancer deaths. Sunitinib is a broad-spectrum inhibitor of tyrosine kinase receptors mostly known for its anti-angiogenic effects. We tested the therapeutic effects of sunitinib in pancreatic cancer using the Ela-myc transgenic mouse model. We showed that Ela-myc pancreatic tumors express PDGFR and VEGFR in blood vessels and epithelial cells, rendering these tumors sensitive to sunitinib by more than only its anti-angiogenic activity. However, sunitinib treatment of Ela-myc mice with either early or advanced tumor progression had no impact on either survival or tumor burden. Further histopathological characterization of these tumors did not reveal differences in necrosis, cell differentiation, angiogenesis, apoptosis or proliferation. In stark contrast, in vitro sunitinib treatment of Ela-myc- derived cell lines showed high sensitivity to the drug, with increased apoptosis and reduced proliferation. Correspondingly, subcutaneous tumors generated from these cell lines completely regressed in vivo after sunitinib treatments. These data point at the pancreatic tumor microenvironment as the most likely barrier preventing sunitinib treatment efficiency in vivo. Combined treatments with drugs that disrupt tumor fibrosis may enhance sunitinib therapeutic effectiveness in pancreatic cancer treatment.

Matèries (anglès)

Citació

Citació

MARTÍNEZ-BOSCH, Neus, GUERRERO, Pedro enrique., MORENO, Mireia, JOSÉ, Anabel, IGLESIAS, Mar, MUNNÉ-COLLADO, Jessica, ANTA, Héctor, GIBERT, Joan, OROZCO, Carlos alberto, VINAIXA, Judith, FILLAT I FONTS, Cristina, VIÑALS CANALS, Francesc, NAVARRO, Pilar. The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. _Oncotarget_. 2016. Vol. 7, núm. 30, pàgs. 48265-48279. [consulta: 26 de desembre de 2025]. ISSN: 1949-2553. [Disponible a: https://hdl.handle.net/2445/150708]

Exportar metadades

JSON - METS

Compartir registre